



Code: 532 321

Code: CADILAHC

January 23, 2021

Listing Department

BSE LIMITED

P J Towers, Dalal Street, Fort,

Mumbai - 400 001

Listing Department

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, Bandra Kurla Complex,

Bandra (E),

Mumbai - 400 051

Re.: Press Release

Dear Sir/Madam,

Please find enclosed a copy of press release dated January 23, 2021 titled "Zydus Cadila receives final approval from USFDA for Liothyronine Sodium Tablets."

The contents of the press release give full details.

AHMEDABAD

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,

For, CADILA HEALTHCARE LIMITED

DHAVAL N. SONI
COMPANY SECRETARY

Encl.: As above



ress Release

Press Release

Press Release

Press Release

Press Release

Press Release

Press Release

Zydus Cadila receives final approval from USFDA for Liothyronine Sodium Tablets

Ahmedabad, 23 January, 2021

Zydus Cadila has received final approval from the USFDA to market Liothyronine Sodium Tablets USP, 5 mcg, 25 mcg, and 50 mcg (US RLD: Cytomel Tablets).

Liothyronine is a man-made form of thyroid hormone which is used to treat an underactive thyroid (hypothyroidism). It replaces or provides more thyroid hormone, which is normally made by the thyroid gland. The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 312 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally.

Phone: +91-079-71800000, +91-079-48040000 www.zyduscadila.com CIN: L24230GJ1995PLC025878